Ignite Creation Date:
2024-07-17 @ 10:55 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06490055
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-21
Brief Title:
Predicting the Efficacy in Advanced Gastric Cancer
Sponsor:
City of Hope Medical Center
Organization:
City of Hope Medical Center
Study Overview
Official Title:
Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
With advances in chemotherapy for gastric cancer it is important to identify patients who will respond effectively to specific therapies This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer
Detailed Description:
The combination of paclitaxel and ramucirumab is a potent standard second-line therapy for patients with advanced gastric cancer but approximately 30 of patients do not respond to treatment Failure to respond to second-line therapy can lead not only to disease progression but also to deterioration of the patients health and loss of the opportunity to receive other treatments that originally had the potential to be curative This study aims to predict the efficacy of second-line treatment paclitaxel plus ramucirumab in patients with gastric cancer using liquid biopsies small RNA Prediction using pre-treatment blood may allow patients who do not respond to treatment to choose other treatment options This study aims to establish a tool that will enable noninvasive pre-treatment selection which could lead to personalized treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None